Soft-tissue augmentation of the face has been attempted for many years using a variety of substances. inorganic substances have included silicone gel, polyethylene, polyacrylamide gel, and expanded polytetrafluoroethylene. Problems with these substances have included extrusion, severe granuloma formation, and palpability.1 Organic substances have included mica, ivory, liquid paraffin, and coral. More recently, human and bovine collagen have been used with variable success. Limitations have included loss of volume over a relatively short period and the potential for allergic reactions in up to 3% of patients.2 Naturally occurring fillers, including hyaluronic acid, poly-L-lactic acid, and autologous fat, are becoming more popular. However, none of these substances has proved to be the ideal injectable material. Migration, host immunological responses, absorption, and rejection have been the biggest hurdles. The ideal implant should be noncarcinogenic, nonteratogenic, nontoxic, nonimmunogenic (no foreign body or inflammatory reaction), nonresorbable, easy to work with, and malleable. The material should have a tactile feel similar to that of tissue, have a low or zero extrusion rate, allow biointegration of the implant with the surrounding tissue, and be cost-effective.3 Attempts to reach these goals have led to the introduction of calcium hydroxylapatite (CaHA) (also referred to as calcium hydroxyapatite).